PainChek is pleased to announce that the European Patent Office (EPO) has issued a Notice of Acceptance.
The patent will enable PainChek to safeguard the intellectual property of its pain assessment and monitoring technology within the European market. This includes exclusive rights to the commercialisation of its technology across the 39 member states of the European Patent Organisation, until 2035.
“This acceptance letter is the precursor to a fully granted patent, securing our intellectual property in the significantly large European markets which is key to our global strategy, including the UK where we continue to demonstrate growing adoption of PainChek®.”
– Philip Daffas, PainChek CEO & Managing Director
The new patent is in addition to the existing patents granted in the USA, Japan, and China providing intellectual property protection of PainChek’s technology in some of the world’s largest healthcare markets.
You can read PainChek’s official ASX announcement here.
